Treatment Outcome for Flexible Dosing Buprenorphine Maintenance Treatment

REFERENCES

• Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274:361–372.
   PubMed Web of Science ®Google Scholar
• Cowan A, Ph D. Buprenorphine: The basic pharmacology revisited. J Addict Med 2007; 1(2):68–72.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569–580.
   PubMed Web of Science ®Google Scholar
• Liguori A, Morse WH, Bergman J. Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 1996; 277:462–472.
   PubMed Web of Science ®Google Scholar
• Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96:627–632.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17–25.
   PubMed Web of Science ®Google Scholar
• Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004; 13(1):S42–S66.
   PubMedGoogle Scholar
• Caldiero R, Parran T, Jr, Adelman C, Piche B. Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict 2006; 15:1–7.
   PubMed Web of Science ®Google Scholar
• White J, Bell J, Saunders J, Williamson P, Makowska M, Farquharson A, Beebe K. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103:37–43.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441–452.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999; 56(3):191–203.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53(5):401–407.
   PubMed Web of Science ®Google Scholar
• Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4(1):3–7.
   PubMedGoogle Scholar
• Comer S, Collins E, Fischman MW. Buprenorphine sublingual tablets: Effects on IV heroin self-administration by humans. Psychopharmacology 2001; 154:28–37.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Schuh K, Hopper J, Schuster C, Johanson C. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002; 160:344–352.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 2003; 361(9358):662–668.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998; 93:475–486.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and METH for opioid dependence. N Engl J Med 2000; 343:1290–1297.
   PubMed Web of Science ®Google Scholar
• Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, Nilsson LH, Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am J Psychiatry 2007; 164(5):797–803.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend 2010; 107(2–3):253–256.
   PubMed Web of Science ®Google Scholar
• Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20(6):806–814.
   PubMed Web of Science ®Google Scholar
• Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz LR, Thase ME, Weiss RD, Gastfriend DR, Woody GE, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT. Psychosocial treatments for cocaine dependence: National institute on drug abuse collaborative cocaine treatment study. Arch Gen Psychiatry 1999; 56:493–502.
   PubMed Web of Science ®Google Scholar
• Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70:315–325.
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162:340–349.
   PubMed Web of Science ®Google Scholar
• Simpson DD, Joe GW, Fletcher BW, Hubbard RL, Anglin MD. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507–514.
   PubMed Web of Science ®Google Scholar